Recce Pharmaceuticals (ASX:RCE) EV-to-EBIT : -12.49 (As of Apr. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Recce Pharmaceuticals's Enterprise Value is A$135.90 Mil. Recce Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.88 Mil. Therefore, Recce Pharmaceuticals's EV-to-EBIT for today is -12.49.

The historical rank and industry rank for Recce Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

ASX:RCE' s EV-to-EBIT Range Over the Past 10 Years
Min: -78.53 Med: 0 Max: 0
Current: -12.49

ASX:RCE's EV-to-EBIT is ranked worse than
100% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs ASX:RCE: -12.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Recce Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was A$105.17 Mil. Recce Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.88 Mil. Recce Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.35%.

Recce Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Recce Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals EV-to-EBIT Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

-8.28

-20.74

-10.43

-13.35

-8.53

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial											-	-13.35	-	-8.53	-

Competitive Comparison of Recce Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Recce Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recce Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's EV-to-EBIT falls into.

Recce Pharmaceuticals EV-to-EBIT Calculation

Recce Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	135.897	/	-10.882
	=	-12.49

Recce Pharmaceuticals's current Enterprise Value is A$135.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.88 Mil.

Recce Pharmaceuticals (ASX:RCE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Recce Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-10.882	/	105.17057
	=	-10.35 %

Recce Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was A$105.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.88 Mil.

Recce Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals (ASX:RCE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines